Elanco Animal Health Inc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Elanco Animal Health completed a 25,000-square-foot expansion at its Elwood facility, increasing production capacity fourfold and adding 70 new jobs. The $150 million investment, planned through 2028, includes a new pilot plant and lab. Elanco manufactures USDA-approved treatments for pets at the site.
Elanco Animal Health completed a $120 million expansion of its Elwood facility, adding 25,000 square feet and increasing production capacity for monoclonal antibodies. The expansion is expected to support the development of next-generation animal health treatments. Company and government officials celebrated the completion.
Elanco Animal Health completed a $120M expansion in Kansas, quadrupling monoclonal antibody capacity. The expansion supports launches of Befrena and Trutect, key to Elanco's pet therapeutics strategy. The company projects $5.8B revenue and $297.2M earnings by 2029, with a 24% upside to its current price.
Over the past 7 days, alphai's AI scored 7 news stories mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bullish: 5 bullish, 2 neutral, and 0 bearish.
Recent ELAN coverage spans financial news, insider activity and corporate actions.
In the last 30 days, ELAN insiders filed 5 SEC Form 4 transactions — 5 purchases ($1.5M) and no sales. The most active reporter was Kurzius Lawrence Erik with 1 filing.
The expansion increases production capability, potentially boosting future revenue and earnings.
The expansion positions Elanco to increase output of animal‑health monoclonal antibodies, potentially boosting future revenue.
The expanded capacity could boost revenue from new antibody treatments but adds fixed costs, increasing execution risk.
The expansion could improve revenue growth prospects but short‑term impact is limited; price may stay pressured by overvaluation signals.
Capacity boost and strong product demand could lift earnings outlook.
alphai scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elanco Animal Health completed a 25,000-square-foot expansion at its Elwood facility, increasing production capacity fourfold and adding 70 new jobs. The $150 million investment, planned through 2028, includes a new pilot plant and lab. Elanco manufactures USDA-approved treatments for pets at the site.
2 min readElanco Animal Health completed a $120 million expansion of its Elwood facility, adding 25,000 square feet and increasing production capacity for monoclonal antibodies. The expansion is expected to support the development of next-generation animal health treatments. Company and government officials celebrated the completion.
1 min readElanco Animal Health completed a $120M expansion in Kansas, quadrupling monoclonal antibody capacity. The expansion supports launches of Befrena and Trutect, key to Elanco's pet therapeutics strategy. The company projects $5.8B revenue and $297.2M earnings by 2029, with a 24% upside to its current price.
2 min readElanco Animal Health (ELAN) completed a 25,000-square-foot expansion to boost biologics production, including monoclonal antibody therapies. The company's P/S ratio is 2.51, slightly above its historical median, with a GF Score of 68. Insiders have purchased $2.6M in shares over the past year. GF Value™ estimates ELAN is 50.5% overvalued at $25.09 per share.
2 min readElanco (ELAN) completed a $120M expansion of its Kansas facility, increasing mAb production capacity over fourfold. Demand for its new dog treatment, Befrena, is twice expectations, with unconstrained supply expected by early 2027. Additional $30M investment planned through 2028.
2 min readElanco Animal Health (ELAN) completed a 25,000-square-foot expansion of its Kansas facility, boosting monoclonal antibody production. The $120M expansion supports demand for new products like Befrena, with another $30M planned by 2028. Elanco aims to meet growing pet health care demand, citing strong market priorities.
2 min readOn Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp
3 min readKurzius Lawrence Erik purchased 40,000 shares of Elanco Animal Health Inc (ELAN) at $23.40 ($0.94M total) on 2026-08-20.
1 min readO'Neill Shiv (GC AND CORP SEC) purchased 3,998 shares of Elanco Animal Health Inc (ELAN) at $23.58 on 2026-08-18.
1 min readHarrington Michael J purchased 5,000 shares of Elanco Animal Health Inc (ELAN) at $21.82 ($0.11M total) on 2026-08-12.
2 min read
